Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 8, 2011, Pages 701-710

  Cheung, Kin Jip ^a   Tilleman, Kelly ^b   Deforce, Dieter ^b   Colle, Isabelle ^a   Moreno, Christophe ^c,d   Gustot, Thierry ^c,d   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c Department of Gastroenterology and Hepatopancreatology ^*  (Belgium)

^d ERASME HOSPITAL   (Belgium)

Author keywords

biomarker; hepatitis C; liver fibrosis; proteins; proteomics; serum

Indexed keywords

ALPHA 2 MACROGLOBULIN; ASPARTATE AMINOTRANSFERASE; GALECTIN 3; HAPTOGLOBIN; HEMOPEXIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS; THROMBOCYTE;

ADULT; AGED; ALPHA-MACROGLOBULINS; BIOLOGICAL MARKERS; BIOPSY; BLOOD PROTEINS; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HEMOPEXIN; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROTEOME; YOUNG ADULT;

EID: 79960698298     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283471b74     Document Type: Article

References (67)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-218. (Pubitemid 40385459)
2. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 (Suppl 1):S59-S67. (Pubitemid 36511853)
3. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006; 364:33-60. (Pubitemid 43120627)
4. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362:2095-2100. (Pubitemid 38035201)
5. Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26:21S-28S. (Pubitemid 27388067)
6. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52. (Pubitemid 32634271)
7. Marcellin P, Asselah T, Ripault MP, Boyer N. Treatment of chronic hepatitis C. Minerva Gastroenterol Dietol 2004; 50:29-36. (Pubitemid 38649524)
8. Lo Re V III, Kostman JR. Management of chronic hepatitis C. Postgrad Med J 2005; 81:376-382. (Pubitemid 40834903)
9. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495-500. (Pubitemid 32164902)
10. Pinzani M. Liver fibrosis. Springer Semin Immunopathol 1999; 21:475-490.
11. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457. (Pubitemid 37466971)
12. Cholongitas E, Senzolo M, Standish R, Marelli L, Quaglia A, Patch D, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006;125:710-721.
13. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55:569-578.
14. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38:427-432. (Pubitemid 36606313)
15. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618.
16. Burke MD. Liver function: test selection and interpretation of results. Clin Lab Med 2002; 22:377-390. (Pubitemid 34755909)
17. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99:1160-1174. (Pubitemid 38917824)
18. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51:1867-1873. (Pubitemid 41368177)
19. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075. (Pubitemid 32322537)
20. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41:935-942. (Pubitemid 39575660)
21. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, KonatéA, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42:1373-1381. (Pubitemid 43260040)
22. Fabris C, Smirne C, Toniutto P, Coletta C, Rapetti R, Minisini R, et al. Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. Clin Chem Lab Med 2008; 46:253-259.
23. Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004; 50:1299-1300. (Pubitemid 38970635)
24. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526. (Pubitemid 36919874)
25. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1:845-867.
26. Parent R, Beretta L. Proteomics in the study of liver pathology. J Hepatol 2005; 43:177-183. (Pubitemid 40805289)
27. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. Proteomics in liver fibrosis is more than meets the eye. Eur J Gastroenterol Hepatol 2008; 20:450-464. (Pubitemid 351533883)
28. Bischoff R, Luider TM. Methodological advances in the discovery of protein and peptide disease markers. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 803:27-40. (Pubitemid 38340636)
29. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009; 16:418-429.
30. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 2007; 53:1792-1799. (Pubitemid 47509672)
31. White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, et al. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med 2007; 5:33.
32. Gravel P,Walzer C, Aubry C, Balant LP, Yersin B, Hochstrasser DF, Guimon J. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. Biochem Biophys Res Commun 1996; 220:78-85. (Pubitemid 26106802)
33. Cheung KJ, Libbrecht L, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol 2010; 22:1066-1073.
34. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
35. Bedossa P, Poynard T; The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24:289-293. (Pubitemid 26260021)
36. Everitt B. An R and S-plus companion to multivariate analysis. 1st ed. London: Springer; 2005.
37. Press S,Wilson S. Choosing between logistic regression and discriminantanalysis. J Am Stat Assoc 1978; 73:699-705.
38. Worth A, Cronin M. The use of discriminant analysis, logistic regression and classification tree analysis in the development of classification models for human health effects. J Mol Struc-Theochem 2003; 622:97-111.
39. Fawcett T. An introduction to ROC analysis. Pattern Recogn Lett 2006; 27:861-874.
40. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134:1670-1681. (Pubitemid 351615414)
41. Denzer UW, Luth S. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol 2009; 23:453-460.
42. Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973; 133:709-724.
43. Tiggelman AM, Boers W, Moorman AF, de Boer PA, Van der Loos CM, Rotmans JP, Chamuleau RA. Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within schistosoma mansoni egg granulomas. Hepatology 1996;23:1260-1267.
44. Kawser CA, Iredale JP, Winwood PJ, Arthur MJP. Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clinical Science 1998; 95:179-186. (Pubitemid 28401268)
45. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42:1589-1600. (Pubitemid 26354735)
46. Tolosano E, Fagoonee S, Hirsch E, Berger FG, Baumann H, Silengo L, Altruda F. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood 2002;100:4201-4208. (Pubitemid 35402055)
47. Vitalis Z, Altorjay I, Tornai I, Palatka K, Kacska S, Palyu E, et al. Phenotypic polymorphism of haptoglobin: a novel risk factor for the development of infection in liver cirrhosis. Hum Immunol 2011; 72:348-354.
48. Ang IL, Poon TC, Lai PB, Chan AT, Ngai SM, Hui AY, et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res 2006;5:2691-2700. (Pubitemid 44595171)
49. Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta 2001; 312:13-23. (Pubitemid 32913576)
50. Tolosano E, Altruda F. Hemopexin: structure, function, and regulation. DNA Cell Biol 2002; 21:297-306.
51. Tolosano E, Fagoonee S, Morello N, Vinchi F, Fiorito V. Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal 2009; 12:305-320.
52. Das S, Mandal M, Chakraborti T, Mandal A, Chakraborti S. Structure and evolutionary aspects of matrix metalloproteinases: a brief overview. Mol Cell Biochem 2003; 253:31-40. (Pubitemid 37321709)
53. Debruyne EN, Vanderschaeghe D, Van VlierbergheH, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem 2010; 56:823-831.
54. Iacovazzi PA, Cozzolongo R, Lanzillotta E, Frisullo S, Guerra V, Correale M. Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients. Immunopharmacol Immunotoxicol 2008; 30:687-700.
55. Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med 2001; 39:961-965. (Pubitemid 33062248)
56. Kittl EM, Hofmann J, Hartmann G, Sebesta C, Beer F, Bauer K, Huber KR. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med 2000;38:205-208. (Pubitemid 30386689)
57. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25:212-217. (Pubitemid 26276635)
58. Almasio PL, Di Marco V, Bonura C, Fuschi P, Camma C, Lo Iacono O, et al. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. Dig Dis Sci 1999; 44:1013-1019. (Pubitemid 29205615)
59. Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003; 48:2788-2795. (Pubitemid 37280607)
60. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172:288-298. (Pubitemid 351282017)
61. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103:5060-5065.
62. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996; 56:4530-4534. (Pubitemid 26330466)
63. Fukaya Y, Shimada H, Wang LC, Zandi E, DeClerck YA. Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J Biol Chem 2008; 283:18573-18581.
64. Hellstern S, Sasaki T, Fauser C, Lustig A, Timpl R, Engel J. Functional studies on recombinant domains of Mac-2-binding protein. J Biol Chem 2002; 277:15690-15696. (Pubitemid 34967842)
65. Anand BS. Cirrhosis of liver. West J Med 1999; 171:110-115.
66. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239-244. (Pubitemid 36920560)
67. Pinzani M. Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched. Gut 2006; 55:310-312. (Pubitemid 43268265)